Develops therapies for cardiovascular diseases, focusing on novel treatments and therapeutic innovations.
NewAmsterdam Pharma Company N.V., based in Naarden, the Netherlands, is an advanced biopharmaceutical firm focused on developing innovative therapies to advance patient care within the realm of metabolic diseases. Established as a late-stage player in the industry, NewAmsterdam Pharma is dedicated to addressing critical medical needs through its robust pipeline of therapeutic candidates.
At the forefront of its development efforts is obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. This compound is undergoing various clinical trials both as a monotherapy and in combination with ezetimibe to lower LDL-C levels, particularly targeting cardiovascular diseases. In addition to its cardiovascular applications, obicetrapib is also being evaluated in Phase 2a clinical trials for its potential efficacy in treating Alzheimer's disease, highlighting NewAmsterdam Pharma's commitment to exploring diverse therapeutic avenues.
Headquartered in Naarden, NewAmsterdam Pharma Company N.V. leverages its strategic location in Europe to drive forward its mission of advancing transformative therapies. With a focus on scientific rigor and clinical innovation, the company aims to deliver meaningful advancements that improve outcomes and quality of life for patients worldwide.